Prevention of Postoperative Complications by Negative Pressure Therapy After Complex Breast Cancer Surgery

Last updated: December 1, 2025
Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cancer

Breast Cancer

Treatment

Dressing

Negative pressure therapy (NPT)

Clinical Study ID

NCT06265558
PROICM 2023-08 TPN
  • Ages > 18
  • Female

Study Summary

There is little scientific data concerning the use of negative pressure therapy after immediate breast reconstruction.

That strategy of treatment-reconstruction has expanded increasingly since the last years.

The current literature reports only 3 studies on the use of preventive negative pressure therapy in oncologic breast surgery.

Moreover, all three are retrospective, case-control studies with serious limitations.

The largest published series reports a reduction in the overall complication rate from 15.9% to 8.5%, and a significant reduction in several criteria: infection, scar dehiscence and necrosis. However, the study presents significant biases, with non-comparable populations in terms of comorbidities, surgical procedure performed, inclusion periods (and therefore experience in performing oncological surgery).

There was also a high probability of under-assessment or postponement of post-operative complications, which is typical of published retrospective surgical studies.

The published results therefore strongly encourage further investigation of negative pressure therapy in oncological breast surgery.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Female ≥ 18 years

  2. Patient with unilateral invasive or in situ breast carcinoma

  3. Patient with or without neoadjuvant treatment

  4. Patient presenting an indication for complex breast surgery by mastectomy withimmediate breast reconstruction by implant or oncoplasty by T-shaped mammoplasty.

  5. Patient presenting at least one of the following risk factors for scarringdisorders:

  • Obesity with Body Mass Index BMI ≥ 30 and/or Cup size ≥ E

  • Active smoking or smoking cessation for less than one month

  • Diabetes

  • History of homolateral breast radiotherapy

  • Long-term corticosteroid therapy

  1. Patient to have signed informed consent prior to study entry

  2. Willingness and ability to comply with scheduled visits, treatment plan, laboratorytests and other study procedures.

  3. Patient affiliated with a health insurance plan.

Exclusion

Exclusion Criteria:

  1. Legal incapacity or limited legal capacity. Medical or psychological conditionspreventing the patient from completing the study or signing the consent form.

  2. Pregnant or breast-feeding patient as determined in medical records as part ofstandard patients care and follow-up

  3. Patient under guardianship or safeguard of justice

  4. Patient participating in an interventional study with the objective of wound healing

  5. Any concurrent or planned surgical procedure on the contralateral breast

Study Design

Total Participants: 254
Treatment Group(s): 2
Primary Treatment: Dressing
Phase:
Study Start date:
April 15, 2025
Estimated Completion Date:
July 31, 2027

Study Description

In 2022, excisional surgery is still one of the mainstays of breast cancer treatment. The excisional surgery is often combined with adjuvant treatments, which may include medical treatments such as chemotherapy, targeted therapies and immunotherapy, hormone therapy and radiotherapy. All these treatments have toxicities that impact on patients' quality of life.

One of the main complications of surgery is scarring. The rate is around 2% for "simple" breast surgery (conservative breast surgery - total mastectomy). This rate can rise sharply in the case of "complex" breast surgery, such as high-level oncoplasty, or mastectomy with Immediate Breast Reconstruction (IBR). This rate of surgical wound complications (ischemia, necrosis, dehiscence, infection) reached 20% in our local series of Immediate Breast Reconstruction (IBR) by prosthesis. This rate may exceed 30% in some series, depending on the surgical technique and the population, in cases of smoking, diabetes, previous radiotherapy, obesity and large breast volume. The increasing prevalence of these risk factors in the population means that scarring disorders must be taken into account in daily cancer care.

The impact of these scarring disorders is manifold:

  • Delayed initiation of adjuvant therapy with an impact on overall survival.

  • Cosmetic impact of scarring

  • Possible loss of prosthetic breast reconstruction

  • Patient dissatisfaction, with increased burden of care

  • Overall impact on patient quality of life

  • Economic impact linked to the length of care over time (consumption of dressing materials and personal time) Preventing the onset of wound-healing disorders is therefore vital in order to avoid these multiple consequences for the patient and the healthcare system.

In breast surgery, the use of preventive NPT (Negative Pressure Therapy) has been little studied. The NPT has been used mainly in cosmetic surgery procedures such as breast reduction, with results in favor of NPT. The most comprehensive study is a multicenter randomized trial which included 200 patients scheduled for bilateral breast reduction. In this trial, the comparison was made between the 2 breasts, each patient being her own control. The calculation of the number of subjects was based on a reduction in the complication rate from 20% to 10% (i.e., a 50% reduction). The study was positive, showing a reduction in the dehiscence rate at day 21 from 26% to 16%. In this study, patients were under-selected, and around 40% had risk factors for complications. A second randomized study, with similar methodology and judgment criteria, included 32 patients undergoing bilateral breast reduction. The results of this study are significant, but unfortunately there weren't much detail in the publication.

There is little scientific data concerning the use of negative pressure therapy after immediate breast reconstruction. There are very few data on the use of Negative pressure Therapy (NPT) after immediate Breast Reconstruction (IBR), a treatment-reconstruction strategy that has been expanding rapidly since recent years. The current literature reports only 3 studies on the use of preventive Negative pressure Therapy (NPT) in oncologic breast surgery. All three are retrospective, case-control studies with serious limitations. The largest published series involved 356 patients and 665 breasts. A reduction was reported in the overall complication rate from 15.9% to 8.5%, and a significant reduction in several criteria: infection, seroma, scar dehiscence and necrosis. However, the study presents significant biases, with non-comparable populations in terms of co-morbidities, surgical procedure performed, inclusion periods (and therefore experience in performing oncological surgery). There was also a high probability of under-assessment or postponement of post-operative complications, which is typical of published retrospective surgical studies.

The published results therefore strongly encourage further investigation of Negative Pressure Therapy (NPT) in oncological breast surgery.

Our hypothesis, then, is that preventive NPT in the immediate post-operative phase of complex breast surgery can prevent the onset of post-operative scarring disorders and shorten the time to complete healing.

To date, there are no randomized prospective studies of NPT in complex oncologic breast surgery. Randomized studies already published in general surgery provide a good level of evidence for the efficacy of NPT in preventing local post-operative complications. The latest systematic review and meta-analysis found a reduction in the risk of surgical site infection, from 13% to 8.8%, all types of surgery included. The benefit on the risk of dehiscence in general surgery is less strong, but a 30% reduction was found in a meta-analysis of studies involving only a preventive NPT device, a device widely used throughout the world.

In view of these results from randomized trials in general surgery and non-oncological breast surgery, and the results of retrospective studies in oncological breast surgery, a randomized trial must be carried out. This randomized controlled trial will be pragmatic, incorporating an intermediate analysis, given the endpoint evaluating the reduction in complications in a surgical context, to rapidly meet our objectives with a sufficient level of evidence to have an immediate impact on patients and modify practice.

Connect with a study center

  • Centre Georges-François Leclerc

    Dijon, Côte d'Or 21079
    France

    Site Not Available

  • Centre Georges-François Leclerc

    Dijon 3021372, Côte d'Or 21079
    France

    Site Not Available

  • Centre Hospitalier de Nîmes

    Nîmes 2990363, GARD 30900
    France

    Active - Recruiting

  • Centre Hospitalier de Nîmes

    Nîmes, Gard 30900
    France

    Site Not Available

  • Institut Bergonié

    Bordeaux, Gironde 33076
    France

    Site Not Available

  • Institut Bergonié

    Bordeaux 3031582, Gironde 33076
    France

    Site Not Available

  • Centre Hospitalier de Montpellier

    Montpellier, Hérault 34090
    France

    Active - Recruiting

  • Institut régional du Cancer de Montpellier

    Montpellier, Hérault 34298
    France

    Site Not Available

  • Centre Hospitalier de Montpellier

    Montpellier 2992166, Hérault 34090
    France

    Active - Recruiting

  • Institut régional du Cancer de Montpellier

    Montpellier 2992166, Hérault 34298
    France

    Active - Recruiting

  • Institut de Cancérologie de l'Ouest

    Angers, Maine Et Loire 49055
    France

    Site Not Available

  • Institut de Cancérologie de l'Ouest

    Angers 3037656, Maine Et Loire 49055
    France

    Active - Recruiting

  • Centre Léon Bérard

    Lyon, Rhône 69373
    France

    Site Not Available

  • Centre Léon Bérard

    Lyon 2996944, Rhône 69373
    France

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.